Home › CTI BioPharma Corp (CTIC) Upgraded at Zacks Investment Research
 

Keywords :   


CTI BioPharma Corp (CTIC) Upgraded at Zacks Investment Research

2015-12-29 06:13:09| Biotech - Topix.net

The brokerage currently has a $1.50 price objective on the biopharmaceutical company's stock. Zacks Investment Research 's price target would indicate a potential upside of 16.28% from the stock's current price.

Tags: research investment corp upgraded

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
17.05More people seek help for debts as fee scrapped
17.05Hunt hints at another National Insurance tax cut
17.05Alan Bates rejects second Post Office compensation offer
17.05Severn Trent boss defends multi-million pay packet
17.05Coptis Marks 25th Anniversary
17.05Farm Progress America, May 17, 2024
17.05Farm Progress America, May 17, 2024
17.05China pours billions into crisis-hit property market
More »